Plasma p‐tau217, NfL, GFAP diagnostic performance and biomarker profiles in Alzheimer's disease, frontotemporal dementia, and psychiatric disorders, in a prospective unselected neuropsychiatry memory clinic

Documenti analoghi

• Mindful Moderation: Differential Relationships Between Psychological Distress and NfL, GFAP and p ‐tau217 by Diagnostic Group
  di: Christa Dang, et al.
  Pubblicazione: (2025)
• Clarifications and response to “Validating plasma biomarkers for distinguishing neurodegenerative and psychiatric disorders” by Boccardi et al.
  di: Dhamidhu Eratne, et al.
  Pubblicazione: (2026)
• The Markers in Neuropsychiatric Disorders Study (The MiND Study): progress of a large nationwide Australian blood biomarker study and platform for collaborations to improve diagnosis and care of dementia and other brain conditions
  di: Dhamidhu Eratne, et al.
  Pubblicazione: (2024)
• Transforming dementia diagnostics and care: developing a novel, cost‐effective technology to facilitate widespread and cost‐effective clinical implementation of neurofilament light and other biomarkers
  di: Dhamidhu Eratne, et al.
  Pubblicazione: (2025)
• Performance of plasma p‐tau217 and NfL in an unselected memory clinic setting
  di: Rebecca Z. Rousset, et al.
  Pubblicazione: (2024)